|
1) DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997; 77: 75-197
|
|
|
|
2) Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991; 71: 659-82
|
|
|
|
|
|
3) Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009; 54: 1195-201
|
|
|
|
|
4) Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc. 1953; 152: 1501-4
|
|
|
|
|
|
5) Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-81
|
|
|
|
|
|
6) Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009; 361: 932-4
|
|
|
|
|
|
7) Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovasucular events. Hypertens Res. 2010; 33: 515-20
|
|
|
|
|
|
8) Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87: VI40-8
|
|
|
|
|
|
9) Fukuta H, Hayano J, Ishihara S, et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant. 2003; 18: 318-25
|
|
|
|
|
|
10) Petersson M, Friberg P, Eisenhofer G, et al. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005; 26: 906-13
|
|
|
|
|